New drug combo tested to fight tough brain cancer in seniors
NCT ID NCT04022980
Summary
This study tested whether adding the immunotherapy drug nivolumab after standard chemotherapy is safe and effective for older adults (65+) with a rare brain cancer called primary CNS lymphoma. The goal was to see if this extra treatment could help keep the cancer from coming back for a longer period. Researchers first checked the safety of the drug combination in a small group, then looked at how well it worked to control the disease over two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN AND NERVOUS SYSTEM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Brookline, Massachusetts, 02215, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
The University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.